X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (91) 91
oncology (68) 68
female (66) 66
male (60) 60
aged (59) 59
middle aged (58) 58
adult (49) 49
melanoma (40) 40
cancer (32) 32
survival (26) 26
treatment outcome (25) 25
aged, 80 and over (24) 24
prognosis (23) 23
care and treatment (21) 21
immunotherapy (21) 21
skin neoplasms - pathology (20) 20
melanoma - drug therapy (19) 19
melanoma - pathology (19) 19
neoplasm staging (18) 18
adolescent (16) 16
metastasis (16) 16
carcinoma (15) 15
chemotherapy (15) 15
ipilimumab (15) 15
therapy (14) 14
young adult (14) 14
antineoplastic agents - therapeutic use (13) 13
antineoplastic combined chemotherapy protocols - therapeutic use (13) 13
clinical trials (13) 13
denmark (13) 13
metastases (13) 13
skin neoplasms - drug therapy (13) 13
survival analysis (13) 13
survival rate (13) 13
analysis (12) 12
dermatology (12) 12
diagnosis (12) 12
disease-free survival (12) 12
management (12) 12
melanoma - mortality (12) 12
melanoma - secondary (12) 12
cutaneous melanoma (11) 11
dose-response relationship, drug (11) 11
metastatic melanoma (11) 11
radiotherapy (11) 11
double-blind method (10) 10
endocrinology & metabolism (10) 10
hematology, oncology and palliative medicine (10) 10
medicine, research & experimental (10) 10
research (10) 10
time factors (10) 10
immunology (9) 9
malignant-melanoma (9) 9
patients (9) 9
skin neoplasms - mortality (9) 9
thyroid cancer (9) 9
abridged index medicus (8) 8
antibodies, monoclonal - therapeutic use (8) 8
breast neoplasms - drug therapy (8) 8
cancer and oncology (8) 8
cancer och onkologi (8) 8
expression (8) 8
follow-up studies (8) 8
kaplan-meier estimate (8) 8
melanoma - therapy (8) 8
risk factors (8) 8
skin neoplasms - therapy (8) 8
thyroid neoplasms - pathology (8) 8
tumors (8) 8
biological response modifiers (7) 7
carcinoma, squamous cell - radiotherapy (7) 7
denmark - epidemiology (7) 7
interferon (7) 7
interferon-alpha (7) 7
interleukin-2 (7) 7
melanoma - genetics (7) 7
phase-ii (7) 7
prospective studies (7) 7
skin neoplasms (7) 7
trial (7) 7
angiogenesis (6) 6
antibodies, monoclonal - adverse effects (6) 6
antineoplastic agents - adverse effects (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
dose-response relationship, radiation (6) 6
drug therapy (6) 6
head and neck neoplasms - radiotherapy (6) 6
high-risk melanoma (6) 6
immune checkpoint (6) 6
iodine radioisotopes - therapeutic use (6) 6
medicine & public health (6) 6
medicine, general & internal (6) 6
mutation (6) 6
pharmacology & pharmacy (6) 6
proportional hazards models (6) 6
retrospective studies (6) 6
safety (6) 6
salvage therapy (6) 6
usage (6) 6
adjuvant therapy (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2014, Volume 384, Issue 9940, pp. 319 - 328
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 611 - 622
Journal Article
Journal of translational medicine, ISSN 1479-5876, 2011, Volume 9, Issue 1, pp. 204 - 204
Background: Ipilimumab, a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4, has demonstrated an improvement in overall survival in... 
Tumor biomarker | Cytotoxic t-lymphocyte antigen-4 | Tumor-infiltrating lymphocytes | Ipilimumab | Melanoma | Indoleamine 2,3-dioxygenase | Foxp3 | SURVIVAL | MEDICINE, RESEARCH & EXPERIMENTAL | SOLID TUMORS | INFILTRATING LYMPHOCYTES | Cytotoxic T-lymphocyte antigen-4 | melanoma | PERIPHERAL-BLOOD | OVARIAN-CARCINOMA | PROGNOSTIC-FACTOR | THERAPY | ipilimumab | REGULATORY T-CELLS | tumor-infiltrating lymphocytes | indoleamine 2,3-dioxygenase | FoxP3 | tumor biomarker | ABSOLUTE LYMPHOCYTE COUNT | Immunohistochemistry | Prospective Studies | Skin Neoplasms - drug therapy | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | RNA, Messenger - metabolism | Dose-Response Relationship, Drug | Young Adult | Antineoplastic Agents - adverse effects | Melanoma - genetics | Aged, 80 and over | Biomarkers, Tumor - metabolism | Adult | Female | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Skin Neoplasms - pathology | Tumor Microenvironment - drug effects | Drug Administration Schedule | Antibodies, Monoclonal - pharmacology | RNA, Messenger - genetics | Treatment Outcome | Melanoma - pathology | Polymorphism, Genetic | Antibodies, Monoclonal - administration & dosage | Melanoma - drug therapy | Skin Neoplasms - genetics | Aged | Neoplasm Staging | Usage | Messenger RNA | Physiological aspects | Genetic aspects | Research | Biological markers | Gene expression | Studies | Clinical trials | Medical research | Cancer
Journal Article
The lancet oncology, ISSN 1470-2045, 2012, Volume 13, Issue 9, pp. 897 - 905
Summary Background No effective standard treatment exists for patients with radioiodine-refractory, advanced differentiated thyroid carcinoma. We aimed to... 
Hematology, Oncology and Palliative Medicine | CRITERIA | MALIGNANT-TUMORS | SOLID TUMORS | ONCOLOGY | PAPILLARY | SORAFENIB | INHIBITOR | CARCINOMA | ZD6474 | Carcinoma | Humans | Middle Aged | Bone Neoplasms - secondary | Male | Antineoplastic Agents - therapeutic use | Diarrhea - chemically induced | Young Adult | Lung Neoplasms - secondary | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Female | ErbB Receptors - antagonists & inhibitors | Thyroid Neoplasms - mortality | Double-Blind Method | Kaplan-Meier Estimate | Electrocardiography - drug effects | Heart Conduction System - drug effects | Lymphatic Metastasis | Thyroid Cancer, Papillary | Disease-Free Survival | Adenocarcinoma, Follicular | Thyroid Neoplasms - drug therapy | Carcinoma, Papillary | Piperidines - therapeutic use | Quinazolines - therapeutic use | Piperidines - adverse effects | Adolescent | Quinazolines - adverse effects | Skin Neoplasms - secondary | Survival Analysis | Thyroid Neoplasms - secondary | Aged | Thyroid Neoplasms - pathology | Tyrosine | Care and treatment | Thyroid cancer | Clinical trials | Product development | Metastasis | Vascular endothelial growth factor | Cancer | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 373, Issue 1, pp. 23 - 34
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 375, Issue 19, pp. 1845 - 1855
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2019, Volume 381, Issue 16, pp. 1535 - 1546
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 2, pp. 144 - 152
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2008, Volume 359, Issue 1, pp. 31 - 42
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2009, Volume 27, Issue 23, pp. 3794 - 3801
Purpose This phase II study investigated the efficacy and tolerability of motesanib, an investigational, highly selective inhibitor of vascular endothelial... 
AMG-706 |